Dr. Hristos Kaimakliotis on Predictive Markers in Bladder Cancer

Video

Hristos Kaimakliotis, MD, assistant professor, Indiana University School of Medicine, discusses predictive markers in bladder cancer.

Homologous recombination repair-deficiency (HRD) and cell cycle progression (CCP) have been identified in DNA repair pathways as potential predictors of tumor behaviors, says Kaimakliotis.

After investigating HRD and CCP assays, it was determined that higher CCP and HRD scores were associated with pathological complete responses (pCR) and decreased risk of recurrence.

In a mutation analysis, it was determined that P53 and RB1 mutations were associate with pCRs as well.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,